Search PubMed⌕ Search

Biomedical subjects

C Benvenuti

Publications and source records attributed to C Benvenuti.

At least 109 records · Page 6Linked to original sources
PubMed1984

Pharmacokinetics of oral and rectal flurbiprofen in children.

Eight subjects, aged 6-12 years and weighing 18.8-36.7 kg, received single doses of flurbiprofen 50 or 75 mg (corresponding to 1.4-2.7 mg/kg) as syrup and suppository in a Latin square design. Half-life (2.7-3.2 h), elimination constant (0.22-0.26 h-1), area under the plasma level curve (72.4-77.3 micrograms X h X ml-1) and time to reach the concentration peak (1-0.75 h) were similar after the syrup and suppository. Flurbiprofen showed equivalent bioavailability after oral and rectal administration and the same pharmacokinetic profile was confirmed in children as observed in adults.

Administration, Oral↗
PubMed1984

A multi-centre general practice study evaluating the efficacy and tolerance of ibuprofen in common painful conditions.

An open, multi-centre study in general practice was carried out in 1842 patients presenting with non-serious painful conditions to assess the effectiveness and tolerance of ibuprofen. Patients received daily doses ranging from 400 mg to 2400 mg for up to 1 month; most took between 1200 mg and 1600 mg per day for about 1 week. Assessments of pain severity on a visual analogue scale showed that 82% of patients with moderate to severe pain derived benefit from treatment, the analgesic effect of a dose often lasting up to 6 hours. The best response was seen in patients with dysmenorrhoea and dental pain, and although headache was less responsive than other painful conditions the overall rate of positive results for this diagnosis reached 75% in the opinion of both physicians and patients. Approximately 14% of patients reported side-effects, mostly gastro-intestinal with abdominal pain predominating.

Administration, Oral↗
PubMed1983

Controlled study on flurbiprofen and diclofenac in the treatment of rheumatic disorders.

Forty patients affected by various rheumatic disorders (mainly osteoarthritis) were treated with flurbiprofen (300 mg daily) or diclofenac (200 mg daily) in a two-week, parallel group, randomized trial. Both drugs were clinically effective in all the parameters except for fingertip-to-floor distance and ESR. Flurbiprofen proved to be more effective than diclofenac in reducing pain on movement (p less than 0.01) and number of swollen joints (p less than 0.05). The doctor's overall assessment favoured flurbiprofen (p less than 0.10). The incidence and severity of side-effects were low and similar with the two drugs.

Clinical Trials as Topic↗
PubMed1983

Steroid-sparing action of flurbiprofen and indomethacin in rheumatoid arthritis: a nine-week study.

Thirty out-patients with rheumatoid arthritis aged from 3 yrs. (+/- 0.5 SEM) were included in a between-patient controlled trial comparing effectiveness and safety of flurbiprofen 300 mg daily and indomethacin 150 mg daily. The duration of the treatment was nine weeks. Both drugs allowed to reduce the initial dose of corticosteroids administered (-21% on flurbiprofen and -12% on indomethacin) and were effective in improving clinical signs of the disease such as number of swollen joints, grip strength, articular index and morning stiffness. Flurbiprofen was better tolerated (p less than 0.01).

Adolescent↗
PubMed1983

Pharmacokinetics of cimetidine in patients with unresponsive duodenal ulcer.

The pharmacokinetics of cimetidine after an oral dose of 400 mg were measured in 18 patients with duodenal ulcer, 9 refractory and 9 responders. The peak plasma concentration of cimetidine (2.13 +/- 0.17 micrograms/ml vs 1.43 +/- 0.04 micrograms/ml), the area under the plasma concentration curve (A.U.C.) between 0 to 8 hours after cimetidine (8.49 +/- 0.29 micrograms/ml/h vs 5.83 +/- 0.25 micrograms/ml/h), and the time span in which cimetidine was above 0.5 micrograms/ml (I.C.50) (401 +/- 8.86 min vs 296 +/- 20 min) were all found to be greater in responding patients than in non-responders to the therapy. No differences were detectable between the two groups in urinary excretion, T 1/2 of cimetidine or percentage inhibition (1%) of maximal pentagastrin-stimulated acid output (MAO). The results indicate that clinical healing of duodenal ulcer after cimetidine is related principally to the drug's pharmacokinetics, i.e. to its absorption from the small bowel, and that some other therapeutic approaches might be tried before surgery in cases of duodenal ulcer refractory to cimetidine.

Adult↗
PubMed1982

The influence of carbon dioxide and nitrous oxide on pain during laparoscopy: a double-blind, controlled trial.

A prospective and controlled trial in 92 patients was done to determine the influence on the onset of pain during laparoscopy under local anesthesia by age, sex, perlaparoscopic guided liver biopsy, the presence of adhesions and of ascites, and the type of gas (CO2 or N2O) used in the abdominal cavity. N2O was found less pain provoking, while other factors had no influence on the onset of pain.

Adult↗
PubMed1982

A prospective study on Candida as a gastric opportunistic germ.

Report of results from a study on the presence of Candida as a stomach opportunistic germ in 149 patients consecutively undergoing gastroscopy. Candida was isolated in 23 patients (15.4%). None of the following factors influenced the appearance of the fungus as an opportunist in the stomach: age, sex, smoking, alcohol intake, associated systemic diseases, concomitant gastroduodenal diseases or gastric histological findings. The only favoring factor revealed was that of cardiotonic treatment in 43.5% of the patients with a positive outcome, and in 15.1% of those with a negative outcome (p less than 0.01). Species isolated were Candida albicans in 15 patients (65.2%), Candida tropicalis, Candida pseudo-tropicalis and Candida glabrata in 2 patients each (8.7%), Candida krusei and Candida guillermondi in 1 patient each.

Age Factors↗
PubMed1982

Oral and intravenous pharmacokinetics of cimetidine in liver cirrhosis.

The bioavailability of p.o. and i.v. cimetidine was studied in 12 patients with compensated liver cirrhosis in a crossover study. Single doses of 200 and 400 mg cimetidine were used for both administration routes. Plasma concentration and urinary recovery were determined by the HPLC method. The pharmacokinetic data observed in these patients do not differ from those of normal subjects and patients. A positive correlation between AUC and cimetidine oral dose was found. Oral bioavailability of cimetidine was about 94% compared to that of the i.v. route. The p.o. dose of 400 mg produced AUC values similar to the i.v. dose of 400 mg. After 400 mg cimetidine p.o. the mean peak plasma level was higher and the time for which plasma levels remained above 0.5 mg/l was longer. There were no significant differences between plasma cimetidine levels after the intravenous administration of 200 and 400 mg. The urinary recovery of cimetidine was significantly higher after intravenous administration independently of the given dose. The pharmacokinetics of cimetidine does not appear to be altered in liver cirrhosis.

Administration, Oral↗
PubMed1981

[Double-blind evaluation of the effectiveness of cimetidine in the arrest of hemorrhages due to gastroduodenal peptic lesions].

40 patients with an endoscopic diagnosis of bleeding gastric or duodenal lesions have been examined in a double blind study. The haemorrhages were subdivided into slight and serious on the basis of objective parameters. Cimetidine (1.2 g/die i.v.) or placebo in a preparation indistinguishable from the drug were administered to patients. Arrest of the haemorrhage was evaluated on the basis of clinical and endoscopic criteria, and the study was pursued up to 96 hours from the start of bleeding. The effect of cimetidine proved greater than that of the placebo in serious haemorrhage, particularly where due to gastric lesions, but no differences were seen between drug and placebo in the slight haemorrhages.

Adult↗
PubMed1980

Double-blind double-dummy crossover comparison of the effect of a single dose of cimetidine and trithiozine on gastric secretion.

Twelve patients with duodenal ulcer were admitted to a double-blind double-dummy single dose study in which the H2-receptor antagonist effect of Cimetidine and the activity of Trithiozine, endowed with an unknown mechanism, on gastric acid secretion were compared. For the balanced incomplete block design each patient received two out of four treatments. The single doses tested were 200 and 400 mg of both drugs. Cimetidine reduced all the parameters investigated, while Trithiozine increased basal acid output and acid concentration and did not affect maximal and peak acid output, basal and maximal volume and maximal acid concentration. The multiple range comparison between mean adjusted differences of the four doses were significantly in favour of Cimetidine, except for PAO, basal volume and basal acid concentration, despite the remarkable percent difference between Cimetidine and Trithiozine. In this study, Cimetidine confirmed its inhibitory properties, and Trithiozine did not appear to be an antisecretory agent.

Adult↗